| |
Learn de-risking strategies in our whitepaper and explore the future of precision treatments from our survey of 100+ oncology professionals. 
|
|
Today’s Big NewsOct 1, 2024 |
| By Kevin Dunleavy Johnson & Johnson is laying off 231 employees in New Jersey and Bayer is cutting 57 positions in the state. The cuts follow other Big Pharma layoff rounds in the state. |
|
|
|
By Eric Sagonowsky No large pharma company has traversed this decade's ups and downs quite like Pfizer. As the company rolls ahead with a large restructuring campaign, some staffers in Ireland will soon feel the effects. |
By Nick Paul Taylor Gritstone bio has brought in bankers to explore “potential value-maximizing strategies” after its phase 2 colorectal cancer vaccine data fell short of the runaway success needed to transform its fortunes. |
By Conor Hale With Flyrcado's extended half-life of nearly two hours—more than ten times that of other cardiac diagnostic agents—clinicians would be able to put patients on a treadmill for exercise stress testing. |
|
These awards honor CROs that excel in innovation, quality, and leadership, highlighting their crucial role in advancing life sciences and improving patient outcomes. Enter now! 
|
|
By Andrea Park Astellas Pharma is slowing things down in the inaugural consumer-facing marketing blast for eye disease drug Izervay. |
By James Waldron IGM Biosciences ended last year laying off staff and streamlining its cancer pipeline. Now, the company has become the latest to join a hot trend in cell therapy biotech—pivoting from oncology to autoimmune disease. |
By Fraiser Kansteiner With its first approval in hand, privately held IntraBio is embarking upon the difficult task of marketing a drug for an ultra-rare disease. Still, with months of prep work and outreach complete, the company is already proving it can hit the ground running. |
By Conor Hale Pi-Cardia’s ShortCut device received a de novo clearance to open up old heart valve implants and clear the blood flow into the coronary arteries. |
By Nick Paul Taylor Phreesia has generated evidence that exposing patients to vaccine messages at the point of care boosts the vaccination rate, including among historically marginalized groups. |
By Gabrielle Masson BioMarin is adding kindling to the R&D fire, striking a match with CAMP4 Therapeutics for rights to select two targets identified by the biotech’s RNA platform designed to help create treatments for genetic diseases. |
By Fraiser Kansteiner Metsera is teaming up with generics and specialty drug maker Amneal Pharmaceuticals, which will now serve as the biotech’s “preferred supply partner” for developed markets. |
By Joseph Keenan Piramal Pharma Solutions, a unit of Indian CDMO Piramal Pharma, plans to spend $80 million to expand its sterile injectables manufacturing facility in Lexington, Kentucky. |
By Ben Adams Nonprofit heart health group the Family Heart Foundation has joined forces with Amgen for a new cholesterol health campaign. |
Fierce podcasts Don’t miss an episode |
| In this week's "The Top Line," Fierce journalists discuss key issues from promising but debated lung cancer data at recent conferences. |
|
|---|
|
|
|
Wednesday, October 16, 2024 | 2pm ET / 11am PT Join experts as they delve into the distinct strategies required for developing ADCs and RIT, focusing on how medical imaging can accelerate clinical trials and drug approval. Register now to gain practical insights into optimizing clinical trials and advancing cancer therapies through cutting-edge imaging techniques. 
|
|
Whitepaper Unlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
Whitepaper Unique Solutions for Drug Discovery and Development Sponsored by: Cell Signaling Technology |
Whitepaper When the fate of your company hangs in the balance, you need expert guidance to navigate the complexities of biotechnology development and to make informed decisions. Sponsored by: WCG |
Whitepaper Power non-invasive, self-sampling solutions using the Colli-Pee™️ first-void urine collection device. Learn more. Sponsored by: DNA Genotek |
Whitepaper Facing roadblocks in drug development? Uncover how phase-appropriate technology transfers can help you navigate challenges and speed up your journey to market. Sponsored by: Veranova |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| Submissions Deadline Sept 12th |
|
|
| |
|
